Moreover, we formerly demonstrated that MIF is a key protein in the treatment of NAFLD with salidroside, and molecular docking, molecular dynamics, and SPR affirmed the binding activity between salidroside and MIF [21]. This evidence concerns the gene MIF and metabolic dysfunction-associated steatotic liver disease.